

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2016

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 001-28911

**CANNABIS SCIENCE, INC.**

(Exact name of registrant as specified in its charter)

Nevada

91-1869677

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

6946 N Academy Blvd, Suite B #254 Colorado Springs, CO

80918

(Address of principal executive offices)

(Zip Code)

(888) 263-0832

**(Registrant's telephone number, including area code)**

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a not-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer

Non-accelerated filer  Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes  No

Number of common shares issued and outstanding at May 4, 2016: 1,835,805,296

Number of common shares outstanding at March 31, 2016: 1,843,855,296

Number of Class A common shares outstanding at May 18, 2016: 0

**CANNABIS SCIENCE, INC.**

**FORM 10-Q**

For the Period Ended March 31, 2016

**TABLE OF CONTENTS**

|   | <u>Page</u> |
|---|-------------|
| <b>PART I FINANCIAL INFORMATION</b>   | 3           |
| Item 1. Consolidated Financial Statements   | 3           |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | 5           |
| Item 3. Quantitative and Qualitative Disclosures about Market Risk                            | 9           |
| Item 4. Controls and Procedures   | 9           |
| <br><b>PART II OTHER INFORMATION</b>  | <br>10      |
| Item 1. Legal Proceedings   | 10          |
| Item 1A. Risk Factors   | 10          |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds                           | 10          |
| Item 3. Defaults Upon Senior Securities   | 11          |
| Item 4. Mine Safety Disclosures.  | 11          |
| Item 5. Other Information   | 11          |
| Item 6. Exhibits and Certifications   | 12          |

**PART I FINANCIAL INFORMATION.**

**ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS**

**CANNABIS SCIENCE, INC.**

|   | Page No. |
|---|----------|
| Consolidated Balance Sheets as at March 31, 2016 and December 31, 2015...   | F-1      |
| Consolidated Statements of Operations and Other Comprehensive Income (Loss) for three months ended March 31, 2016 and 2015... | F-2      |
| Consolidated Statements of Cash Flows for the three months ended March 31, 2016 and 2015...                                   | F-3      |
| Consolidated Statements of Stockholders' Deficit for the three months ended March 31, 2016                                    | F-4      |
| Notes to Consolidated Financial Statements...   | F-5      |

**CANNABIS SCIENCE, INC.**  
**CONSOLIDATED BALANCE SHEETS**  
March 31, 2016 and December 31, 2015

|   | March 31, 2016<br>(UNAUDITED)<br>\$ | December 31,<br>2015<br>\$ |
|---|-------------------------------------|----------------------------|
| <b>ASSETS</b>   |                                     |                            |
| <b>Current Assets</b>   |                                     |                            |
| Cash  | 15,192                              | 61,971                     |
| Other receivables   | 56,314                              | 39,366                     |
| Loans receivable, related party   | 22,516                              | 37,516                     |
| Inventory   | 84,267                              | 19,311                     |
| Prepaid expenses and deposits   | 162,838                             | 156,750                    |
| <b>Total current assets</b>   | <b>341,127</b>                      | <b>314,914</b>             |
| Property farming license (Note 7)   | 25,000                              | -                          |
| Deposits (Note 8)   | 1,152,850                           | 971,500                    |
| Equity method investee (Note 9)   | 198,362                             | 128,927                    |
| Goodwill (Note 10)  | 162,154                             | 170,689                    |
| Intangibles, net of accumulated amortization (Note 10)  | 204,250                             | 215,000                    |
| <b>TOTAL ASSETS</b>   | <b>2,083,743</b>                    | <b>1,801,030</b>           |
| <b>LIABILITIES AND STOCKHOLDERS' DEFICIT</b>  |                                     |                            |
| <b>Current Liabilities</b>  |                                     |                            |
| Accounts payable  | 747,381                             | 680,215                    |
| Accrued expenses, primarily management fees (Note 4)  | 1,933,654                           | 1,614,654                  |
| Advances from related parties (Note 4)  | 422,080                             | 414,135                    |
| Management bonuses  | 300,000                             | 300,000                    |
| Notes payable to stockholders (Note 5)  | 1,360,658                           | 1,406,513                  |
| <b>Total current liabilities and total liabilities</b>  | <b>4,763,773</b>                    | <b>4,415,517</b>           |
| <b>Stockholders' Deficit</b>  |                                     |                            |
| Series A Preferred stock, \$0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at March 31, 2016 and December 31, 2015         | 1,000                               | 1,000                      |
| Common stock, \$.001 par value, 3,000,000,000 shares authorized, 1,843,855,296 issued and outstanding as of March 31, 2016 and 1,581,855,296 at December 31, 2015 | 1,843,856                           | 1,581,856                  |
| Common stock, Class A, \$.001 par value, 100,000,000 shares authorized, 0 issued and outstanding as of March 31, 2016 and December 31, 2015                       | -                                   | -                          |
| Prepaid consulting  | (2,641,794)                         | (3,209,032)                |
| Common Stock receivable   | (1,090,000)                         | (381,500)                  |
| Additional paid-in capital  | 131,089,023                         | 127,942,191                |
| Accumulated deficit   | (131,308,104)                       | (128,017,132)              |
| Cumulative exchange translation   | (20,592)                            | (18,496)                   |
| Equity attributable to common shareholders  | (2,126,611)                         | (2,101,113)                |
| Non-Controlling interest  | (553,419)                           | (513,374)                  |
| <b>Total stockholders' deficit</b>  | <b>(2,680,030)</b>                  | <b>(2,614,487)</b>         |
| <b>TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</b>  | <b>2,083,743</b>                    | <b>1,801,030</b>           |

The accompanying notes are an integral part of these consolidated financial statements.

**CANNABIS SCIENCE, INC.**  
**CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE (LOSS)**  
**(UNAUDITED)**

| FOR THE THREE MONTHS ENDED MARCH 31                     | 2016<br>\$           | 2015<br>\$       |
|---|----------------------|------------------|
| <b>Revenue</b>  | <b>2,925</b>         | -                |
| <b>Cost of Goods Sold</b>                               | <b>1,598</b>         | -                |
| Operating Expenses                                      |                      |                  |
| Investor relations                                      | 157,000              | 5,000            |
| Professional fees                                       | 81,690               | 25,040           |
| Net loss on settlement of liabilities                   | 588,645              | 2,358,076        |
| Depreciation and amortization                           | 19,285               | -                |
| Research and development                                | 163,000              | 197,336          |
| General and administrative                              | 2,391,689            | 1,651,092        |
| Total operating expenses                                | <b>3,401,309</b>     | 4,236,544        |
| Net Operating Loss                                      | <b>(3,399,982)</b>   | (4,236,544)      |
| Other Income (Expense)                                  |                      |                  |
| Interest expense, net                                   | (35)                 | (280)            |
| Impairment of goodwill                                  | -                    | (64,421)         |
| Unrealized gain (loss) on equity investee               | 69,000               | (48,750)         |
| Total other income (expense)                            | <b>68,965</b>        | (113,451)        |
| Net Loss  | <b>(3,331,017)</b>   | (4,349,995)      |
| Net Loss attributable to non-controlling interest       | <b>40,045</b>        | 8,525            |
| Net Loss attributable to common shareholders            | <b>(3,290,972)</b>   | (4,341,470)      |
| Other Comprehensive Income                              |                      |                  |
| Foreign exchange translation adjustment                 | (2,096)              | (31,306)         |
| Total other comprehensive income                        | <b>(2,096)</b>       | (31,306)         |
| <b>Net Comprehensive Loss</b>                           | <b>(3,293,068)</b>   | (4,372,776)      |
| Net loss per common share<br>- Basic and diluted        | <b>\$ (0.00)</b>     | <b>\$ (0.00)</b> |
| Weighted average number of<br>common shares outstanding | <b>1,680,393,758</b> | 1,052,605,692    |

The accompanying notes are an integral part of these consolidated financial statements.

**CANNABIS SCIENCE, INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**FOR THE THREE MONTHS ENDED MARCH 31, 2016 and 2015**  
**(UNAUDITED)**

|   | March 31,<br>2016<br>\$ | March 31,<br>2015<br>\$ |
|---|-------------------------|-------------------------|
| <b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>                                |                         |                         |
| Net loss  | (3,331,017)             | (4,349,995)             |
| Adjustments to reconcile net loss to net cash used in operating activities: |                         |                         |
| Depreciation and amortization   | 19,285                  | -                       |
| Stock issued for services   | 1,738,220               | 1,713,671               |
| Stock issued for debt extension   | -                       | -                       |
| Stock options issued for services   | 437,000                 | -                       |
| Loss / (Gain) on equity investee  | (69,000)                | 48,750                  |
| Gain on marketable securities   | -                       | -                       |
| (Gain) / Loss on settlement of liability                                    | -                       | -                       |
| Loss on settlement of debt  | 588,645                 | 2,358,076               |
| Impairment loss on goodwill   | -                       | -                       |
| Warrant expense   | -                       | -                       |
| Foreign exchange translation adjustment                                     | (2,096)                 | (31,306)                |
| Changes in operating assets and liabilities:                                |                         |                         |
| Other receivables   | (16,948)                | 974                     |
| Equity investee   | (435)                   | -                       |
| Inventory   | (64,956)                | -                       |
| Prepaid expenses and deposits   | (6,088)                 | (43,162)                |
| Accounts payable  | 67,166                  | 97,815                  |
| Accrued expenses, primarily management fees                                 | 319,000                 | (118,500)               |
| Loan receivable, related parties  | 22,945                  | 50,000                  |
| <b>NET CASH USED IN OPERATING ACTIVITIES</b>                                | <b>(298,279)</b>        | <b>(273,677)</b>        |
| <b>CASH FLOWS FROM INVESTING ACTIVITIES</b>                                 |                         |                         |
| Advances receivable, related parties  | -                       | -                       |
| Repayment from advances receivable, related party                           | -                       | -                       |
| Property license for cultivation  | (25,000)                | -                       |
| <b>CASH FLOWS USED IN INVESTING ACTIVITIES</b>                              | <b>(25,000)</b>         | <b>-</b>                |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES</b>                                 |                         |                         |
| Proceeds from advances from officers  | -                       | -                       |
| Proceeds from notes payable to stockholders                                 | -                       | -                       |
| Repayments of notes payable to stockholders                                 | -                       | -                       |
| Advances from related parties   | -                       | 51,140                  |
| Proceeds from common stock options exercised                                | 276,500                 | -                       |
| Proceeds from sale of common stock  | -                       | 250,000                 |
| <b>CASH FLOWS PROVIDED BY FINANCING ACTIVITIES</b>                          | <b>276,500</b>          | <b>301,140</b>          |
| <b>NET INCREASE (DECREASE) IN CASH</b>                                      | <b>(46,779)</b>         | <b>27,463</b>           |
| <b>CASH, BEGINNING OF PERIOD</b>  | <b>61,971</b>           | <b>10,061</b>           |
| <b>CASH, END OF PERIOD</b>  | <b>15,192</b>           | <b>37,524</b>           |
| <b>SUPPLEMENTAL CASH FLOW INFORMATION:</b>                                  |                         |                         |
| Common stock issued for services  | 1,170,982               | 5,541,037               |
| Common stock issued for settlement of debt                                  | 634,500                 | 2,538,904               |
| Debt converted into common stock  | 45,855                  | 180,828                 |
| Common stock issued for assets  | -                       | -                       |
| Common stock issued for debt extension                                      | -                       | -                       |
| Common stock issued for options exercised                                   | 1,338,050               | -                       |
| Equity investment in Endocan Corporation                                    | -                       | -                       |
| Accounts payable paid through note payable, stockholder                     | -                       | -                       |

The accompanying notes are an integral part of these consolidated financial statements.

**CANNABIS SCIENCE, INC.**  
**CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT**  
**FOR THE THREE MONTHS ENDED MARCH 31, 2016**  
**(UNAUDITED)**

|  | Common<br>Shares     | Par<br>\$        | Preferred<br>Shares | Par<br>\$    | Additional<br>Paid-In Capital<br>\$ | Prepaid<br>Consulting<br>\$ | Common<br>Stock<br>Receivable<br>\$ | Accumulated<br>Deficit<br>\$ | Foreign<br>Exchange<br>Translation<br>\$ | Non-<br>Controlling<br>Interest<br>\$ | Totals<br>\$       |
|--|----------------------|------------------|---------------------|--------------|-------------------------------------|-----------------------------|-------------------------------------|------------------------------|--|---------------------------------------|--------------------|
| <b>Balance at December 31, 2015</b>                        | <b>1,581,855,296</b> | <b>1,581,856</b> | <b>1,000,000</b>    | <b>1,000</b> | <b>127,942,191</b>                  | <b>(3,209,032)</b>          | <b>(381,500)</b>                    | <b>(128,017,132)</b>         | <b>(18,496)</b>                          | <b>(513,374)</b>                      | <b>(2,614,487)</b> |
| Common stock issued for services                           | 103,000,000          | 103,000          |                     |              | 1,067,982                           | (395,614)                   | -                                   |                              |  |                                       | 775,368            |
| Common stock issued for settlement of liabilities and debt | 45,000,000           | 45,000           |                     |              | 589,500                             |                             | -                                   |                              |  |                                       | 634,500            |
| Common stock issued for private placement                  | -                    | -                |                     |              | -                                   |                             | -                                   |                              |  |                                       | -                  |
| Common stock issued for deposit to acquire assets          | 15,500,000           | 15,500           |                     |              | 165,850                             |                             | -                                   |                              |  |                                       | 181,350            |
| Common stock issued for stock option exercised             | 98,500,000           | 98,500           |                     |              | 1,239,550                           |                             | (708,500)                           |                              |  |                                       | 629,550            |
| Fair Value on option shares not exercised                  |                      |                  |                     |              | 83,950                              |                             |                                     |                              |  |                                       | 83,950             |
| Amortization of shares issued for services                 |                      |                  |                     |              |                                     | 962,852                     |                                     |                              |  |                                       | 962,852            |
| Net loss for the period                                    |                      |                  |                     |              |                                     |                             |                                     | (3,290,972)                  |  | (40,045)                              | (3,331,017)        |
| Foreign exchange translation                               |                      |                  |                     |              |                                     |                             |                                     |                              | (2,096)                                  |                                       | (2,096)            |
| <b>Balance at March 31, 2016</b>                           | <b>1,843,855,296</b> | <b>1,843,856</b> | <b>1,000,000</b>    | <b>1,000</b> | <b>131,089,023</b>                  | <b>(2,641,794)</b>          | <b>(1,090,000)</b>                  | <b>(131,308,104)</b>         | <b>(20,592)</b>                          | <b>(553,419)</b>                      | <b>(2,680,030)</b> |

The accompanying notes are an integral part of these consolidated financial statements.

**CANNABIS SCIENCE, INC.**  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  
March 31, 2016  
(UNAUDITED)

**1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*A. Organization and General Description of Business*

Cannabis Science, Inc. (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 6, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number.

On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTCBB: CBIS.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company formed two operating subsidiaries Cannabis Science BV and Cannabis Science International Holding BV in The Netherlands on May 10<sup>th</sup> and May 6<sup>th</sup>, 2013, respectively, to pursue business opportunities in Europe and worldwide. There are currently minimal operations in the subsidiaries. Agreements and business disclosures are in process.

On November 15, 2013, the Company submitted a patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders." The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD), anxiety, and sleep disorders.

On November 20, 2014, the Company signed an amendment to the license agreement with Apothecary Genetics Investments LLC. Pursuant to the amendment, the Company is acquiring all property, building, and equipment of Apothecary. The Company anticipated closing the purchase in fiscal 2015 once all assets are identified with supported fair market values and the transfer of land title is completed.

*B. Basis of Presentation*

These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars. The Company’s fiscal year end is December 31.

Interim Financial Reporting

While the information presented in the accompanying interim consolidated financial statements is unaudited, it includes all adjustments, which are in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with general accepted accounting principles in the United States of America (“GAAP”). These interim financial statements follow the same accounting policies and methods of application as used in the December 31, 2015 audited financial statements of Cannabis Science, Inc. (the “Company”). All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in the year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the three month periods ended March 31, 2016 and 2015. It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2015 included in our Form 10-K filed with the SEC on file no. 000-28911 161631274 May 9, 2016. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that can be expected for the year ending December 31, 2016.

The following subsidiaries and controlling interests are included with the consolidated financial statements of the Company for the three months ended March 31, 2016:



In 2012, the Company formed Cannabis Science Europe GmbH (“CSE”) to operate joint-venture operations with Dupetit Natural Products Ltd. The JV asset was sold to Endocan Corporation (formerly X-Change Corporation) on December 12, 2012. No operations had commenced at the time of sale of the JV asset. The Company has reignited the CSE by appointing Mr. Alfredo Dupetit on September 19, 2015 as president and chief executive officer of CSE. As recent as January 7, 2016, the Federal Health Ministry in Germany has presented “Cannabis as medicine”, a detailed draft bill that aims to modify the Drug Law and relax the strict measures that regulate the consumption of medical cannabis and, above all, become the main vehicle for everything relating to the plant and its medical users in the country. The Company has reinstated the development of cannabis products in February 2016 for medicinal uses in Germany.

On May 6, 2013, the Company formed Cannabis Science International Holdings B.V. and on May 10, 2013, the Company formed Cannabis Science B.V. for the purpose of wholly-owned operating subsidiaries for the Company’s European and world-wide operations. The Company has commenced some operating activities with cultivation in Spain and product development in 2014. Mario Lap, director of the Company and director and officer of Cannabis Science B.V. manages the day-to-day operations through his private companies MLS BV and MJR BV, both Netherlands registered companies.

On August 6, 2014, the Company signed a proposal letter with Michigan Green Technologies, LLC (“MGT”) to acquire an additional 30.1% equity in MGT and completed the transaction with the principals of MGT under the proposal letter on February 20, 2015 to effectively increase the Company’s equity ownership to 50.1%. As consideration for acquiring the additional 30.1% equity, the Company issued 1,200,000 shares of common stock with a fair market value of \$60,000 to the principals and shareholders of MGT.

On May 6, 2015 the Company announced the Assets acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products. As consideration for acquiring the Assets, which consist of Inventory, Trademark and brand names, and goodwill, the Company issued ten million (10,000,000) shares to the shareholders of Equi-Pharm and they agreed to change its company name. The acquisition was completed on November 16, 2015 and the Company has formed a new wholly owned subsidiary called Equi-Pharm LLC. In the state of Tennessee and start the operation of distributing of existing and new line of products.

For other accounting policies please refer to the Company’s Form 10-K with the SEC on file no. 000-28911 161631274 May 9, 2016.

The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than \$1,000,000,000 in annual gross revenue and did not have much amount as of December 31, 2015, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

## **2. GOING CONCERN**

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate the continuation of the Company as a going concern. The Company reported an accumulated deficit of \$131,308,104 and had a stockholders’ deficit of \$2,680,030 as at March 31, 2016.

In view of the matters described, there is substantial doubt as to the Company's ability to continue as a going concern without a significant infusion of capital. At March 31, 2016, the Company had insufficient operating revenues and cash flow to meet its financial obligations. There can be no assurance that management will be successful in implementing its plans. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

We anticipate that we will have to raise additional capital to fund operations over the next 12 months. To the extent that we are required to raise additional funds to acquire research and growing facilities, and to cover costs of operations, we intend to do so through additional public or private offerings of debt or equity securities. There are no commitment or arrangements for other offerings in place, no guaranties that any such financings would be forthcoming, or as to the terms of any such financings.

Any future financing may involve substantial dilution to existing investors. We had been relying on our common stock to pay third parties for services which has resulted substantial dilution to existing investors.

## **3. FAIR VALUE MEASUREMENTS AND DISCLOSURES**

ASC Topic 820, *Fair Value Measurement*, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to

unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

#### **4. RELATED PARTY TRANSACTIONS**

At March 31, 2016, a total of \$52,500 (December 31, 2015: \$52,500) in loans payable was due to the Company's CFO, Robert Kane, through his company, R Kane Holding Inc., secured by a non-interest bearing promissory note due within 30 days of Michigan Green Technologies (50.1% controlled by the Company) liquidating shares in Cannabis Science, Inc. to repay the debt.

At March 31, 2016, the Company owes \$6,000 (December 31, 2015: \$6,000) to R Kane Holding Inc., which advanced a total of \$6,000 to Dean Law Trust for payment of the Company's expenses in July and August of 2015 with no interest and no security. Loan Payable to R Kane Holding Inc., a company controlled by Mr. Robert Kane, director and CFO totaled \$58,500 and \$0 at March 31, 2016 and 2015 respectively.

At March 31, 2016, the Company owes \$61,902.15 (December 31, 2015: \$61,902.15) to Interstate 101, a shareholder of the Company, with no interest and no security.

At March 31, 2016, the Company owes \$3,164.72 (December 31, 2015: \$3,164.72) to Castor Management Services, a shareholder of the Company, with no interest and no security.

At March 31, 2016, a total of \$191,344 (December 31, 2015: \$191,344) in loans payable was due to Bogat Family Trust, Raymond Dabney the Company's Director and President/CEO as trustee.

At March 31, 2016, \$74,792 (December 31, 2015: \$66,847) was due to MJR BV, owned by Mario Lap director and director and officer of EU subsidiaries.

At March 31, 2016, \$447 (December 31, 2015: \$447) was due to Robert Melamede, former CEO.

At March 31, 2016, the Company held 7,500,000 common shares in the Endocan Corporation (formerly X-Change Corporation) (OTCBB: ENDO) ("Endocan") representing approximately 8.6% of the issued and outstanding shares of Endocan, of which 5,000,000 common shares were acquired at a fair market value of \$150,000 or \$0.03 on December 12, 2012 and 2,500,000 common shares were acquired at a fair market value of \$262,250 or \$0.1049 per share on February 8, 2013. The 5,000,000 common shares were received as consideration for the sale of its rights and interest in the Dupetit Natural Products GmbH joint-venture operating agreement to Endocan under an Asset Purchase Agreement and the 2,500,000 common shares were received as consideration for the sale of its rights and interest in the Maliseet joint-venture operating agreement to Endocan under an Asset Purchase Agreement. The value of the shares at March 31, 2016 and December 31, 2015 was determined to be \$0.015 per share or \$112,500 with the Company recording an unrealized gain on equity investee of \$69,000 for the three months ended March 31, 2016 and \$0.0145 per share or \$108,750 with the Company recording an unrealized loss of \$48,750 for the three months ended March 31, 2015.

On November 5, 2014, the Company transitioned to equity method investee account for the Endocan shares pursuant to ASC 323 recording \$247,500 as the fair value of the shares to its equity method investee account. On December 31, 2015, the Company recorded an impairment on the equity method investee account of \$114,000 in relation to the shares. Robert Kane, CFO and director of the Company is also the CFO and a director of Endocan. Chad S. Johnson, Esq., COO, general counsel and a director is also a director and general counsel for Endocan. Raymond Dabney, CEO is the controlling shareholder of Endocan Corporation.

For the three months ended March 31, 2016, the following related party stock-based compensation was recorded:

| Related Party               | Position                           | Amount             |
|-----------------------------|------------------------------------|--------------------|
| Raymond Dabney <sup>1</sup> | CEO                                | \$ 193,842         |
| Dr. Allen Herman            | Chief Medical Officer              | 25,500             |
| Dr. Roscoe M. Moore, Jr     | Chair of Scientific Advisory Board | 151,000            |
| Robert Kane                 | CFO                                | 215,380            |
| Chad S. Johnson, Esq.       | COO and General Counsel            | 215,380            |
| Mario Lap <sup>1</sup>      | Director                           | 215,380            |
|                             |                                    | <u>\$1,016,482</u> |

<sup>1</sup> Including compensation to entities beneficially owned/control by the related parties

Raymond Dabney, CEO is a controlling shareholder and Chad S. Johnson, COO/General Legal Counsel of ImmunoClin Corporation (OTC: IMCL), respectively. ImmunoClin performs laboratory services, research and pharmaceutical development for the Company through its wholly-owned subsidiary ImmunoClin Limited that operates a laboratory at the London Biosciences Centre.

See Note 6 -Equity Transactions for details of stock issuances to director and officers for services rendered.

Mario Lap, a director of the Company and director and officer its European subsidiaries, is conducting various business activities of the Company in Spain under his personal name and/or his personal holding companies MJR BV and MLS Lap BV until such time as the Company is able to establish a Spanish subsidiary to conduct its own business operations and activities, including but not limited to: operating lease for farms, asset purchases, office and equipment, personnel employment and other business and operating activities as may be required from time-to-time. The Company anticipates having the Spanish subsidiary setup in fiscal 2016 at which time Mario Lap under fiduciary duty will transfer all business operating activities, agreements, and assets to the Company.

Alfredo Dupetit-Bernardi, International Product Development and President & CEO of Cannabis Science Europe GmbH, is conducting product development through the purchase of cannabis products from his personal company, Dupetit Natural Products GmbH.

Notes payable to Embella Holdings Ltd. totaled \$1,108,896 and \$1,108,896 at March 31, 2016 and 2015, respectively. As of March 31, 2016, the Company is in default on the promissory notes due and is negotiating with the debtor to extend the date.

Notes payable to Intrinsic Capital Corp. totaled \$231,260 and \$302,088 at March 31, 2016 and 2015, respectively. See Note 5.

Between January 1, 2015 to March 7, 2015, R. Kane Holding Inc., a company owned by Mr. Robert Kane, director and CFO, had advanced \$52,500 into Michigan Green Technologies, LLC, which is 50.1% controlled by the Company as Loan Payable to R. Kane Holding Inc.

On July 25, 2014, Bogat Family Trust, Raymond Dabney trustee, representing a majority of Series A preferred stockholders, signed a resolution to approve an amendment to the certificate of designation preferences and rights for Series A preferred shares. Pursuant to the amendment filed with the Nevada Secretary of State, the voting rights of Series A preferred stockholders was changed from 1,000 votes per share to 67% of the total vote on all shareholder matters. No common stockholders voted on this amendment.

## **5. NOTES PAYABLE**

As of March 31, 2016, a total of \$1,360,658 (December 31, 2015: \$1,406,513) of notes payable are due to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on January 31, 2012 through February 7, 2014. The Promissory notes were in default on March 31, 2016. All promissory notes are unsecured.

As of March 31, 2016, \$61,902 (December 31, 2015: \$61,902) of loan payable is due to a stockholder, Interstate 101 that is non-interest bearing is due on demand. The loan originated between April 1, 2015 and December 31, 2015 for various expenses of the Company.

As of March 31, 2016, \$3,165 (December 31, 2015: \$3,165) of loan payable is due to a stockholder, Castor Management Services that is non-interest bearing and is due on demand. The loan originated on August 14, 2015 for expenses of the Company.

As of February 7, 2016, the Company has settled the balance of \$45,855 promissory note owed to Stacey R. Lewis since March 21, 2015 and issued 45,000,000 shares of common stock pursuant to a debt settlement agreement with a fair market value of \$634,500.

## **6. EQUITY TRANSACTIONS**

The Company is authorized to issue 3,000,000,000 shares of common stock with a par value of \$0.001 per share. These shares have full voting rights. There were 1,843,855,296 and 1,581,855,296 issued and outstanding as of March 31, 2016 and December 31, 2015, respectively.

The Company is also authorized to issue 100,000,000 shares of common stock, Class A with a par value of \$0.001 per share. These shares have 10 votes per share. There were 0 issued and outstanding as of March 31, 2016 and December 31, 2015.

The Company is also authorized to issue 1,000,000 shares of preferred stock. These shares have full voting rights of 67% on all shareholder matters pursuant to amended certificate of designation filed with the Nevada Secretary of State. There were 1,000,000 issued and outstanding as of March 31, 2016 and December 31, 2015.

As set out below, we have issued securities in exchange for services, properties and for debt, using exemptions available under the Securities Act of 1933.

**During the three months ended March 31, 2016, the Company issued 103,000,000 common stock for services under various executive and consulting agreements as follows:**

On February 1, 2016, the Company entered a management agreement with a consulting firm and agreed to issue 15,000,000 shares of R144 restricted common stock with a fair market value of \$180,000 for investor relation services. The shares were issued on April 7, 2016.

On March 8, 2016, the Company issued 18,000,000 shares R144 restricted common stock to Raymond Dabney, CEO of the Company with a fair market value of \$193,842 for bonus under November 5, 2014 management agreement.

On March 8, 2016, the Company issued 20,000,000 shares R144 restricted common stock to MLS Lap BV, a company controlled a director of the Company with a fair market value of \$215,380 for bonus under June 24, 2013 management agreement.

On March 8, 2016, the Company issued 20,000,000 shares R144 restricted common stock to Chad Johnson, COO/General Council with a fair market value of \$215,380 for bonus and services under November 25, 2014 agreement.

On March 8, 2016, the Company issued 20,000,000 shares R144 restricted common stock to Robert Kane, CFO/director of the Company with a fair market value of \$215,380 for bonus and services under January 20, 2015 agreement.

On March 22, 2016, the Company issued 10,000,000 shares of S-8 registered free-trading common stock under Scientific Advisory Board Agreement of the 2016 Equity Plan with a fair market value of \$151,000.

**During the three months ended March 31, 2016, the Company issued stock pursuant to debt settlement agreements as follows:**

On February 7, 2016, the Company entered into a partial debt settlement agreement with Stacey R. Lewis to retire \$45,855 of the \$75,044 in promissory notes originated on March 21, 2015 and issued 45,000,000 shares of common stock to partially settle the debt for a loss on settlement of \$588,645.

The aforementioned shares for the settlement of debts were issued without legend under an exemption under Rule 144(b)(1) of the Act. Over six months has passed since the debts accrued on the books of the Company; the Seller is not now, and during the three-month period preceding the transaction has not been considered an "affiliate" of the Company. Furthermore, pursuant to Rule 144(d)(1)(i) the Company is, and has been for a period of at least 90 days immediately before the proposed sale, subject to the reporting requirements of section 13 or 15(d) of the Securities and Exchange Act of 1934, and the proposed resale of the Shares in addition to the Company not being considered a shell company under Rule 144(i)(1). All relating shares were issued to settle the debts.

**During the three months ended March 31, 2016, the Company issued stock pursuant to amendment to a property license agreement as follow:**

On January 11, 2016, the Company issued 15,500,000 shares of R144 restricted common stock to Apothecary Genetics Investments with a fair market value of \$181,350 for amendment to a property license agreement on February 9, 2012.

**Stock Options:**

The following options were issued to the Company's V.P of investor relations, CFO and Director for services under a September 16, 2011 agreement:

- (i) the option to purchase 100,000 common shares at ten cents (\$0.10) per share;
- (ii) the option to purchase 100,000 common shares at twenty cents (\$0.20) per share;
- (iii) the option to purchase 500,000 common shares at thirty-five cents (\$0.35) per share; and
- (iv) the option to purchase 1,000,000 common shares at fifty cents (\$0.50) per share.

On February 22, 2016, the Company issued 7,000,000 shares S-8 registered free-trading common stock exercised under Option Agreement of the 2015 Equity Award Plan with exercise price at \$0.01 and a fair market value of \$86,100 to a consultant under management agreement for a total Stock Option of 25,000,000 common shares with fair market value of \$307,500.

On February 22, 2016, the Company issued 6,500,000 shares S-8 registered free-trading common stock exercised under Option Agreement of 2015 Equity Award Plan with exercise price at \$0.01 and a fair market value of \$79,950 to a consultant under management agreement for a total Stock Option of 25,000,000 common shares with fair market value of \$307,500.

On February 29, 2016, the Company issued 25,000,000 shares S-8 registered free--trading common stock under Option Agreement of 2016 Equity Award Plan with exercise price at \$0.01 and a fair market value of \$300,000 to a consultant under management agreement.

On March 22, 2016, the Company issued 15,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2015 Equity Plan with exercise price at \$0.01 and a fair market value of \$226,500 to a consultant under management agreement.

On March 22, 2016, the Company issued 5,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Plan with exercise price at \$0.01 and a fair market value of \$75,500 to a consultant under management agreement.

On March 22, 2016, the Company issued 10,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Plan with exercise price at \$0.01 and a fair market value of \$151,000 to a consultant under management agreement.

On March 22, 2016, the Company issued 15,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Plan with exercise price at \$0.01 and a fair market value of \$226,500 to a consultant under management agreement.

On March 22, 2016, the Company issued 10,000,000 shares of S-8 registered free-trading common stock under Scientific Advisory Board Agreement of the 2016 Equity Plan with a fair market value of \$151,000.

On March 22, 2016, the Company issued 5,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Award Plan with exercise price at \$0.01 and a fair market value of \$75,500.

A summary of the status of the Company's option grants as of March 31, 2016 and the changes during the period then ended is presented below:

|                                       | Shares      | Weighted-Average<br>Exercise Price |
|---------------------------------------|-------------|------------------------------------|
| Outstanding December 31, 2015         | 4,200,000   | \$ 0.195                           |
| Granted                               | 135,000,000 | \$ 0.010                           |
| Exercised                             | 98,500,000  | \$ 0.010                           |
| Expired                               | 2,500,000   | \$ 0.040                           |
| Outstanding March 31, 2016            | 38,200,000  | \$ 0.028                           |
| Options exercisable at March 31, 2016 | 38,200,000  | \$ 0.028                           |

1,700,00 shares of these options at an exercise price of \$0.41 a share, do not expire and continuing indefinitely for the duration of existing management agreement and services thereunder with Robert Kane and 36,500,000 shares at an exercise price of \$0.01 a share expires on February 22, 2017. The weighted average fair value at date of grant for options during year ended March 31, 2016 was estimated using the Black-Scholes option valuation model with the following:

|  |             |
|--|-------------|
| Average expected life in years for options with no expiry            | 2 Years     |
| Average expected life in years for options with expiry on 02/22/2017 | 0.8962 Year |
| Average risk-free interest rate                                      | 2.00 %      |
| Average volatility   | 90 %        |
| Dividend yield   | 0 %         |

## **7. PROPERTY FARMING LICENSE**

On March 24, 2016, the Company entered a 15 years Joint Venture License Agreement with the Ft. McDermitt Allotment land Allotees, which is on the Ft. McDermitt Tribal Reservation, Raymond C. Dabney University, American Education Consulting Group and Cannabis Science, Inc. for a total of ten (10), one (1) acre parcels of land. The project is designed to benefit both the Ft. McDermitt Tribe and Members, and Allotment Allotees. Cannabis Science made an initial payment of \$25,000 for licensing and initial development of the first one (1) acre parcel of land located in Fort McDermitt Tribal Reservation in the State of Nevada, USA. Each one (1) acre parcel of land is specifically designated for placement no more than twelve (12) three (3,000) square foot greenhouses for the production of Cannabis and all Cannabis related products. All harvested products are to be delivered and sold to qualified licensed distribution centers. The Company is to share 40% of the Adjusted Gross Income after deduction of related operating expenses and cost to build the green houses.

## **8. DEPOSITS**

On February 9, 2012, the Company signed a license agreement with Apothecary to produce several Cannabis Science Brand Formulations for the California medical cannabis market. As well, Apothecary will provide research and development facilities with full circle operations including a California laboratory facility for internal research and development, along with 16 unique genetic strains specifically generated and maintained by a cancer survivor who recognizes the importance of proper growth and breeding in addition to investing \$250,000 in research and development in the first 24 months. Apothecary failed to meet several contract provisions including investing \$250,000 in R&D, setting up a laboratory facility, and reporting and remitting license fees owing to the Company. On November 20, 2014, the Company signed an amendment to the license agreement. Pursuant to the amendment, the Company is acquiring all property, building, and equipment of Apothecary in exchange for 14,500,000 Rule 144 restricted stock with a fair market value of \$971,500.

On January 11 2016, the Company signed a second amendment to the license agreement and issued 15,500,000 shares of Rule 144 restricted stock, held in escrow by the Company's attorney, with a fair market value of \$181,350, until the title has been transferred to the company. Pursuant to the second amendment the Company waives prior Royalties owed under any Section of any previous Agreements, and Apothecary shall make business introductions in Jamaica for the Company to work with government licensed growers, laboratories, doctors, and any other mutually agreeable business introductions. Apothecary will immediately sign and transfer ownership of the Northern California Property to the Company and repay and discharge a lien on the property within 12 months signing the second amendment.

The Company recorded an equivalent deposit of \$181,350 for the three months ended March 31, 2016 until the acquisition of assets closes, which is anticipated during the second quarter of 2016.

## **9. EQUITY METHOD INVESTEE**

On November 5, 2014, the Company accounted for its investment and loans in OmniCanna Health Solutions, Inc. (formerly Endocan Corporation) using the equity method pursuant to ASC 323 – Investments – Equity Method and Joint Ventures. In accordance with ASC 323, when the Company does not have a controlling financial interest in an entity but exerts significant influence over the entity's operating and financial policies, the Company accounts for its investment in accordance with the equity method of accounting. This generally applies to cases in which the Company owns a voting or economic interest of between 20 and 50 percent.

The accounting using the equity method is in conjunction with appointment of Raymond Dabney as CEO and director of the Company on November 5, 2014, in addition to Mr. Dabney being a controlling shareholder of the Company since September 2009 and a controlling shareholder of OmniCanna Health Solutions, Inc. since June 2013. Therefore, the Company was deemed to have significant influence and control of OmniCanna Health Solutions Inc.

On November 5, 2014, the Company recorded \$247,500 in marketable securities and \$85,862 (based on currency converted as of March 31, 2016) in loans to OmniCanna Health Solutions, Inc. (hereinafter referred as "OHS") to its equity method investee account in accordance with ASC 323.

An unrealized gain on equity investee account of \$69,000 was recognized for the three months ended March 31, 2016 and an impairment on the equity method investee account of \$48,750 was recognized for the three months ended March 31, 2015 due to the fluctuation in the value of OHS's marketable securities.

**10. GOODWILL and INTANGIBLE ASSETS**

|   | <u>March 31, 2016</u> | <u>December 31, 2015</u> |
|---|-----------------------|--------------------------|
| Intellectual assets, primarily intellectual property and goodwill | \$ 830,988            | \$ 830,988               |
| Less accumulated amortization                                     | <u>(464,584)</u>      | <u>(445,299)</u>         |
| Total intangible assets, net                                      | \$ <u>366,404</u>     | \$ <u>385,689</u>        |

Intangible assets are stated at fair value on the date of purchase less accumulated amortization. Amortization is computed using the straight-line method over the estimated lives of the related assets (5 years for both intellectual assets and Goodwill).

**11. COMMITMENTS**

The Company has lease commitments for its European operations under private companies, MLS Lap B.V. and MJR B.V. owned and controlled by Mario Lap, director of the Company and director and officer of EU subsidiaries. Negotiations are ongoing in regards to preparing finalized agreements between the Company and Mr. Lap's companies.

**12. SUBSEQUENT EVENTS**

There was no transaction subsequent to the three months ended March 31, 2016.

## PART I

### CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

*This Interim Report on Form 10-Q contains forward-looking statements that have been made pursuant to the provisions of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995 and concern matters that involve risks and uncertainties that could cause actual results to differ materially from historical results or from those projected in the forward-looking statements. Discussions containing forward-looking statements may be found in the material set forth under “Business,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in other sections of this Form 10-Q. Words such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Although we believe that our opinions and expectations reflected in the forward-looking statements are reasonable as of the date of this Report, we cannot guarantee future results, levels of activity, performance or achievements, and our actual results may differ substantially from the views and expectations set forth in this Interim Report on Form 10-Q. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations.*

*Readers should carefully review and consider the various disclosures made by us in this Report, set forth in detail in Part I, under the heading “Risk Factors,” as well as those additional risks described in other documents we file from time to time with the Securities and Exchange Commission, which attempt to advise interested parties of the risks, uncertainties, and other factors that affect our business. We undertake no obligation to publicly release the results of any revisions to any forward-looking statements to reflect anticipated or unanticipated events or circumstances occurring after the date of such statements.*

### **ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

This section of this report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this report. These forward-looking states are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions.

#### **Overview of the Company’s Business**

Cannabis Science, Inc. (formerly Gulf Onshore, Inc.) (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 7, 2009, the Company changed its name to Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical cannabis research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In summary, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.



Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide innovative treatment options for unmet medical needs.

Cannabis use has an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.

At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients' lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions.

We are dedicated to working closely with local, national and international regulatory agencies to provide access to high quality, first class cannabinoid pharmaceuticals to those critically in need of new treatments for life threatening and debilitating conditions. Cannabis Science's clinical trial material comes from the cultivation and production facilities that are GMP compliant, surpassing high quality standard industrial and food processing requirements.

The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses.

Our products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. Our immediate focus is to treat one of the most important diseases in the world, cancer.

CS-S/BCC1 is in preparation to enter phase I clinical trials within one to two year. This product is formulated for topical administration to be tested in phase I study, with an indication for skin cancer.

CS-TAT11 is in preclinical development with the indication for infectious disease. Consistent with data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2) which has potential applications in HIV and other infectious diseases.

In November 2013, Cannabis Science submitted patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders." The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD) and anxiety. The first formulation in the series of neurobehavioral disorder-targeted products is the pre-clinical development and use of the invention in food products through a licensing agreement with a strategic partner and related company, OmniCanna Health Solutions, Inc. And Cannabis Science will move forward at the same time with pharmaceutical grade product development.

Cannabis plants have extensive history of medical and agricultural use dating back thousands of years.

To date hundreds of natural constituents covering several chemical classes have been isolated and identified from the Cannabis plant.

Some key phytocannabinoids are:

- tetrahydrocannabinol (THC)
- cannabidiol (CBD)
- cannabigerol (CBG)
- cannabichromene (CBC)
- cannabinol (CBN)

These cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, THC.

Some applications of cannabinoids have been well established in peer-reviewed literature such as for alleviating nausea and stimulating the appetite for people with AIDS and cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with multiple sclerosis and spinal cord injuries.

The pharmacology of THC has been widely studied, while many other identified cannabinoids are still poorly characterized pharmacologically and biologically, with new activities for cannabinoids consistently being discovered.

Cannabis Science is developing novel cannabis based approaches to treat the world's most deadly illnesses. We learn from patients about the healing properties of cannabis medicines. Our immediate focus is the development of cutting edge cancer treatments.

The Company's future endeavors include infectious illnesses, neurobehavioral disorders including attention deficit disorder, post-traumatic stress disorder; and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses.

The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. As such, the mechanisms of phytocannabinoids' biological impact are multidimensional.

While concentrating on our core activities of discovering and developing treatments that will make a meaningful difference in patients' lives, we remain mindful that we have other responsibilities to the clinicians who utilize our drugs, health authorities around the world, our shareholders, our employees, and the communities in which we live and work. We continually strive to improve our corporate responsibility standards and activities, implementing comprehensive ethical standards and undertaking patient and community progressive initiatives.

These principles reflect the mission of Cannabis Science to provide innovative therapeutics for unmet medical needs.

As the industry leader, Cannabis Science consults and leads other emerging businesses that Cannabis Science believes has a preferred business model, one which will mature into a key business model in the future. Our consulting is on the entire "seed to sale" process with a focus on bio-pharmaceutical development.

Cannabis Science is one of the longest standing companies in the cannabis business.

We feel that the correct way is to look at the industry from a bio-pharmaceutical standpoint, in a manner that allows cannabinoid-based products to modulate the endocannabinoid system to treat multiple conditions.

On March 30, 2009, the Company entered into an agreement with Cannex Therapeutics, LLC, ("Cannex") a California limited liability company, and its principal, medical cannabis pioneer and entrepreneur Steven W. Kubby, to acquire all of their interest in certain assets used to conduct a cannabis research and development business. The asset purchase agreement includes all of Cannex's and Kubby's intellectual property rights, formulas, patents, trademarks, client base, hardware and software, including the website [www.phytiva.com](http://www.phytiva.com). The Company and its largest shareholder, K & D Equities, Inc., exchanged a total of 10,600,000 shares of common stock for the assets of Cannex; the Company issued 2,100,000 shares to Cannex, and K & D transferred 8,500,000 shares to Cannex and others. A Form 8-K reflecting this transaction was timely filed.

As part of the Agreement, on April 1, 2009, the Company appointed Mr. Kubby as President and CEO, Richard Cowan as Director and CFO, and Robert Melamede Ph. D., as Director and Chief Science Officer. Each of them was also appointed as a director. All of the Company's current directors then resigned. On April 7, 2010, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number. Its shares now trade under the symbol CBIS.OB. A Form 8-K was timely filed, with a copy of the Asset Acquisition Agreement and Board Resolution ratifying the Agreement provided as exhibits thereto.

On April 7, 2009, the Company changed its name to Cannabis Science, Inc., reflecting its new business mission: Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company obtained a new CUSIP number as well. Cannabis Science Inc. has also launched its new website [www.cannabisscience.com](http://www.cannabisscience.com) reflecting its new name.

On May 7, 2009, the Company common shares commenced trading under the new stock symbol OTC: CBIS.

The Company formed two operating subsidiaries Cannabis Science BV and Cannabis Science International Holding BV in The Netherlands on May 10<sup>th</sup> and May 6<sup>th</sup>, 2013, respectively, to pursue business opportunities in Europe and worldwide.

There are minimal operating activities in the subsidiaries as of September 30, 2015. Mario Lap, a director of the Company and director and officer its European subsidiaries, is conducting various business activities of the Company in Spain under his personal name and/or his personal holding companies MLS Lap B.V. and MJR B.V. until such time as the Company is able to establish a Spanish subsidiary to conduct its own business operations and activities, including but not limited to: operating lease for farms, asset purchases, office and equipment, personnel employment and other business and operating activities as may be required from time-to-time.

On August 6, 2014, the Company signed a proposal letter with Michigan Green Technologies, LLC ("MGT") to acquire an additional 30.1% equity in MGT that would increase the Company's equity ownership to 50.1%. As consideration for acquiring the additional 30.1% equity, the Company has agreed to issue a total of twenty million (20,000,000) shares to the principals and shareholders of MGT over 12 months (see Form 8-K with the SEC on file no. 000-28911 August 8, 2014). The August 6, 2014 offer to purchase an additional 30.1% equity in MGT is on hold until the litigation is resolved.

On January 5, 2015 the Company announced the International release of 8 initial products that will be synergistically produced, distributed and marketed across the Netherlands, Spain and California where Cannabis Science is active and has cannabis production facilities. The products are currently ready for pre-clinical studies, self-medicating patient ailment usage, marketing release, sales and distribution. The company also released The Cannabis Science Patient Access Center (PAC) <http://pac.cannabisscience.com>, in beta version, is now available for patients to track usage and receive updates.

On May 7, 2015 the Company announced the Assets acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products. As consideration for acquiring the Assets, which consist of Inventory, Trademark and brand names, and goodwill, the Company issued ten million (10,000,000) shares to the shareholders of Equi-Pharm and agreed to change its company name. The acquisition was completed on November 16, 2015 and the Company has formed a new wholly owned subsidiary called Equi-Pharm LLC. The Company is working closely with management of Equi-Pharm to expand the product lines.

On May 19, 2015 Cannabis Science announced the expansion of licensing deal with Purple Haze Properties. Cannabis Science and Purple Haze Properties are working together to launch exciting lines of quality cannabis products using scientific genetics and creating an education platform to share information from doctors and patients around the world about the advances of cannabis research.

On May 27, 2015 the Company announced a Historic Collaborative Drug Development deal with IGXBio and its GenePro®, a DNA-based immunotherapeutic that recently received FDA IND approval to enter into human trials. The companies intend to develop a joint protocol to demonstrate potential synergistic effects of their respective drug candidates in HIV, as well as potential new drug candidates. IGXBio is a privately held clinical stage biotechnology company developing advanced DNA immunotherapies for HIV infection, based in Fairway, KS, USA.

On July 16, 2015 Cannabis Science announced guidance in regards to its State-by-State initiatives, including its new product releases. On the forefront are the California new product releases. The Company has signed a research and distribution agreement with Cannabis Science Research Foundation (CSRF). The CSRF will be responsible for the release and distribution of the CBIS products for its initial State-by-State initiatives in California. The CSRF distribution agreement is due to the committed focus CBIS has on its federal drug development program. As a result of this new agreement with CSRF the Cannabis Science Patient Access Center will be moved to the CSRF website as well.

On November 2, 2015 the Company announced a significant collaborative drug development deal with IGXBio Inc., and its GenePro®, a DNA-based immunotherapeutic that recently received FDA IND approval to enter into human trials. The companies developed joint protocols that explore potential synergistic effects of their respective drug candidates, as well as potential new drug candidate opportunities. IGXBio has a drug called GenePro®, which is already registered with the FDA and has an IND number. This expedites the process to seek FDA approval in the future. GenePro® is designed to promote an anti-HIV immune response that facilitates virus control in HIV-infected subjects. There are more than 150 peer-reviewed publications that describe the effectiveness of GenePro®. The inflammatory response that is associated with HIV infection is present at even low levels of viral replication, and is a major causal factor for the morbidities and associated mortality of HIV infection. Low-grade inflammation frequently occurs despite clinically successful anti-retroviral therapy and is associated with increased incidence of heart disease, bone disease, and cancers.

On November 11, 2015, Cannabis Science announced the release of seven original cannabinoid-based animal care products through its wholly owned subsidiary, Equi-Pharm, LLC.

On November 25, 2015 the Company announced positive results from its initial test run of its Pure Decarboxylated CO<sub>2</sub> Oil (PDCO) released through the Cannabis Science Research Foundation (CSRF or the Foundation) to 15 dispensaries and several less fortunate self-medicating patients. This trial, collaborative rollout by CSRF, as contracted by Cannabis Science to the California not-for-profit, was designed to meet two primary goals. The first, to conduct tests on the efficacy of the product for patients; the second, to gather proprietary data based on testimonials from real self-medicating consumers from their firsthand experiences. The feedback received will be used to influence the Company's continuing efforts to bring the best cannabinoid-based formulations to market. On November 30, 2015 Cannabis Science announced the launch of their cannabinoid-formulated capsule product line. The initial capsule formulations released are CBD, Indica, and Sativa; each of the three types of caps will be available in 25mg, 50mg, and 100mg doses and will be provided in two-dose packs with more size options to be made available in the near future.

On December 10, 2015 the Company announced that Cannabis Science entered Select, New High-Dosage product line of CBD, Sativa, and Indica Capsules into the Industry-Famous Emerald Cup Event in Santa Rosa, CA on December 12<sup>th</sup> and 13<sup>th</sup>.

On December 15, 2015 after successful formulation work, Cannabis Science follows through with a full clinical drug development agreement with ImmunoClin to deliver GMP quality pre-clinical data to enter CS-NEURO-1 into a Phase I human study in Europe. After ImmunoClin successfully completed its one-year formulation work for CBIS, focusing on cannabis extracts and cannabinoids, the results are compelling and conclusive. ImmunoClin will, under its class I license, initiate, manage, and coordinate all aspects of the new comprehensive clinical research program on behalf of Cannabis Science. The new program will focus on delivering compliant GMP quality pre-clinical data, including cultivation of CBIS specific cannabis strains, formulation and manufacturing of clinical grade material to enable entry of CS-NEURO-1 and other cannabinoid based products into a Phase I human studies in Europe.

On March 24, 2016, the Company entered a 15 years Joint Venture License Agreement with the Ft. McDermitt Allotment land Allotees, which is on the Ft. McDermitt Tribal Reservation, Raymond C. Dabney University, American Education Consulting Group and Cannabis Science, Inc. for a total of ten (10), one (1) acre parcels of land. The project is designed to benefit both the Ft. McDermitt Tribe and Members, and Allotment Allotees. Cannabis Science made an initial payment of \$25,000 for licensing and initial development of the first one (1) acre parcel of land located in Fort McDermitt Tribal Reservation in the State of Nevada, USA. Each one (1) acre parcel of land is specifically designated for placement no more than twelve (12) three (3,000) square foot greenhouses for the production of Cannabis and all Cannabis related products. All harvested products are to be delivered and sold to qualified licensed distribution centers. The Company is to share 40% of the Adjust Gross Income after deduction of related operating expenses and cost to build the green houses.

The Company is working on several business acquisition and development projects to increase business and revenue generation in 2016 and beyond, including but not limited to: product licensing and royalty agreements, private label hemp product line, consulting, and other strategic acquisitions to support product development, production, and distribution of newly acquire or manufactured cannabis and hemp based products. There can be no assurance that these will be successful in generating revenues in 2016.

### Liquidity

The Company has a working capital deficit of \$4,422,646 as of March 31, 2016 compared to a working capital deficit of \$4,100,603 as of December 31, 2015. There are insufficient liquid assets to meet current liabilities or sustain operations through 2016 and beyond and the Company must raise additional capital to cover the working capital deficit. Management is working on plans to raise additional capital through private placements and lending facilities. The Company currently is relying on existing cash and loans from stockholders to meet its obligations and sustain operations.

The Company has promissory note payment commitments of \$1,340,156 due to stockholders and currently is in default. The Company is negotiating with the debtors to extend the notes payable.

### Contractual Obligations

The Company has various commitments under consulting contracts, debt settlement, licensing agreements, laboratory services agreement, joint development, and joint venture agreement.

### Capital Resources

The Company has additional capital resource requirements for personnel, supplies, research and development, laboratory, cultivation equipment, green houses and scientific equipment of approximately \$5,381,500 over the next 12 months. These capital disbursements are dependent on management's successful raising of capital through private placements and/or lending facilities.

The Company is not currently in good short-term financial standing. We anticipate that we may only generate limited revenues in the near future and we will not have enough positive internal operating cash flow until we can generate substantial revenues, which may take the next two years to fully realize. There is no assurance we will achieve profitable operations. We have historically financed our operations primarily by cash flows generated from the sale of our equity securities and through cash infusions from officers and outside investors in exchange for debt and/or common stock.

### Results of Operations

For the three months ended March 31, 2016 ("2016") as compared to the prior year three months ended March 31, 2015 ("2015"):

The Company had \$2,925 in revenues for the 2016 compared to \$0 for 2015. This increase in revenue is due to assets acquisition of Equi-Pharm.

Our research and development expenses decreased by \$34,336 to \$163,000 for the three months ended March 31, 2016 compared to \$197,336 for the three months ended March 31, 2015.

Net loss on settlement of debt decreased by \$1,769,431 to \$588,645 for the three months ended March 31, 2016 compared to \$2,358,076 for the three months ended March 31, 2015. This decrease is due to the lesser amount of debt settlement and lower share price of the Company's stock relative to loss related to settling debt at a lower share price.

General and administrative expenses increased by \$740,597 to \$2,391,689 for the three months ended March 31, 2016 compared to \$1,651,092 for the three months ended March 31, 2015. This increase is due to increased stock compensation expense pursuant to management consulting and bonus agreements.

The Company is working on several business development projects to generate revenues, including: signing a new license agreement with Ft. McDermitt Indian Tribe in Nevada, and completion with Apothecary Genetics Investments LLC that will generate increased license and royalty revenue, a hemp product line, and other strategic acquisitions to support product development, production, and distribution of newly acquired or manufactured cannabis and hemp based products. The Company's drug development with the pending joint venture with Unistraw is also ongoing through its laboratory services agreement with ImmunoClin Limited in London, UK. In addition, the Company signed an agreement with Equi-Pharm for the commercialization of pet products for distribution in California. Notwithstanding, there can be no assurance that these will be successful in generating revenues in 2016.

## **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Not applicable.

## **ITEM 4. CONTROLS AND PROCEDURES**

Our Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by

this report, have concluded that, based on the evaluation of these controls and procedures, that our disclosure controls and procedures were not effective.

There were no changes in our internal controls or in other factors during the last fiscal quarter covered by this report that have materially affected, or are likely to materially affect the Company's internal controls over financial reporting.

## **PART II OTHER INFORMATION**

### **ITEM 1. LEGAL PROCEEDINGS**

None.

### **ITEM 1A. RISK FACTORS**

Not applicable.

### **ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

During the three months ended March 31, 2016, we have issued securities using exemptions available under the Securities Act of 1933:

As set out below, we have issued securities in exchange for private placements, services and for debt:

On January 11, 2016, the Company issued 15,500,000 shares of R144 restricted common stock to Apothecary Genetics Investments with a fair market value of \$181,350 for amendment to a property license agreement on February 9, 2012.

On January 20, 2016, the Company issued 10,000,000 shares S-8 registered free-trading common stock under Option Agreement of 2015 Equity Award Plan with exercise price at \$0.01 and a fair market value of \$117,000 to a consultant.

On February 1, 2016, the Company entered a management agreement with a consulting firm and agreed to issue 15,000,000 shares of R144 restricted common stock with a fair market value of \$180,000 for investor relation services. The shares were issued on April 7, 2016.

On February 7, 2016, the Company entered into a partial debt settlement agreement with Stacey R. Lewis to retire \$45,854.71 of the \$75,044 in promissory notes originated on March 21, 2015 and issued 45,000,000 shares of common stock to partially settle the debt for a loss on settlement of \$588,645.

On February 22, 2016, the Company issued 7,000,000 shares S-8 registered free-trading common stock exercised under Option Agreement of the 2015 Equity Award Plan with exercise price at \$0.01 and a fair market value of \$86,100 to a consultant under management agreement for a total Stock Option of 25,000,000 common shares with fair market value of \$307,500.

On February 22, 2016, the Company issued 6,500,000 shares S-8 registered free-trading common stock exercised under Option Agreement of 2015 Equity Award Plan with exercise price at \$0.01 and a fair market value of \$79,950 to a consultant under management agreement for a total Stock Option of 25,000,000 common shares with fair market value of \$307,500.

On February 29, 2016, the Company issued 25,000,000 shares S-8 registered free--trading common stock under Option Agreement of 2016 Equity Award Plan with exercise price at \$0.01 and a fair market value of \$300,000 to a consultant under management agreement.

On March 8, 2016, the Company issued 18,000,000 shares R144 restricted common stock to Raymond Dabney, CEO of the Company with a fair market value of \$193,842 for bonus under November 5, 2014 management agreement.

On March 8, 2016, the Company issued 20,000,000 shares R144 restricted common stock to MLS Lap BV, a company controlled a director of the Company with a fair market value of \$215,380 for bonus under June 24, 2013 management agreement.

On March 8, 2016, the Company issued 20,000,000 shares R144 restricted common stock to Chad Johnson, COO/General Council with a fair market value of \$215,380 for bonus and services under November 25, 2014 agreement.

On March 8, 2016, the Company issued 20,000,000 shares R144 restricted common stock to Robert Kane, CFO/director of the Company with a fair market value of \$215,380 for bonus and services under January 20, 2015 agreement.

On March 22, 2016, the Company issued 15,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2015 Equity Plan with exercise price at \$0.01 and a fair market value of \$226,500 to a consultant under management agreement.

On March 22, 2016, the Company issued 5,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Plan with exercise price at \$0.01 and a fair market value of \$75,500 to a consultant under management agreement.

On March 22, 2016, the Company issued 10,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Plan with exercise price at \$0.01 and a fair market value of \$151,000 to a consultant under management agreement.

On March 22, 2016, the Company issued 15,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Plan with exercise price at \$0.01 and a fair market value of \$226,500 to a consultant under management agreement.

On March 22, 2016, the Company issued 10,000,000 shares of S-8 registered free-trading common stock under Scientific Advisory Board Agreement of the 2016 Equity Plan with a fair market value of \$151,000.

On March 22, 2016, the Company issued 5,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Award Plan with exercise price at \$0.01 and a fair market value of \$75,500.

### **ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

### **ITEM 4. MINE SAFETY DISCLOSURES**

N/A

### **ITEM 5. OTHER INFORMATION**

See Financial Statement Notes 4 in regards to stock compensation for officers and directors.



## ITEM 6. EXHIBITS

| Exhibit No. | Document Description  | Filed Herewith (X)<br>Incorporated by ref (I) |
|-------------|---|---|
| 31.1        | Certification by Raymond C. Dabney, Chief Executive Officer, as required under Section 302 of Sarbanes-Oxley Act of 2002. | X   |
| 31.2        | Certification by Robert Kane, Chief Financial Officer, as required under Section 302 of Sarbanes-Oxley Act of 2002.       | X   |
| 32.1        | Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                    | X   |
| 32.2        | Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                    | X   |
| 99.1        | Debt Settlement Agreement   | X   |
| EX-101.INS  | XBRL Instance Document  | X   |
| EX-101.SCH  | XBRL Taxonomy Extension Schema  | X   |
| EX-101.CAL  | XBRL Taxonomy Extension Calculation Linkbase  | X   |
| EX-101.LAB  | XBRL Taxonomy Extension Label Linkbase  | X   |
| EX-101.PRE  | XBRL Taxonomy Extension Presentation Linkbase   | X   |
| EX-101.DEF  | XBRL Taxonomy Extension Definition Linkbase   | X   |

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

### CANNABIS SCIENCE INC.

Date: June 9, 2016

/s/ *Raymond C. Dabney*  
\_\_\_\_\_  
Raymond C. Dabney  
Chief Executive Officer

Date: June 9, 2016

/s/ *Robert Kane*  
\_\_\_\_\_  
Robert Kane  
Chief Financial Officer

## Exhibit 31.1

### Certification of the Chief Executive Officer Pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Raymond C. Dabney, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Cannabis Science, Inc.
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report.
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the Registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the period covered by the quarter report that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting.
5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

By: /s/ Raymond C. Dabney

Raymond C. Dabney

Chief Executive Officer

June 9, 2016

## Exhibit 31.2

### Certification of the Chief Financial Officer Pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Robert Kane, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Cannabis Science, Inc.
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report.
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the Registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the period covered by the quarter report that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting.
5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

By: /s/ Robert Kane

Robert Kane

Chief Financial Officer, Principal Accounting Officer

June 9, 2016

**Exhibit 32.1**

**Certification Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to  
Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of Cannabis Science., (the “Company”) on Form 10-Q for the period ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Raymond C. Dabney, Chief Executive Officer of the Company certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By: /s/ Raymond C. Dabney

Raymond C. Dabney  
Chief Executive Officer  
June 9, 2016

**Exhibit 32.2**

**Certification Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to  
Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of Cannabis Science, Inc., (the “Company”) on Form 10-Q for the period ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert Kane, Chief Financial Officer of the Company certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By: /s/ Robert Kane

Robert Kane

Chief Financial Officer, Principal Accounting Officer

June 9, 2016

**EXHIBIT 99.1**

**DEBT SETTLEMENT AGREEMENT**

**THIS AGREEMENT** is dated for reference the 7<sup>th</sup> day of February 2016.

**BETWEEN:**

**Cannabis Science, Inc.**, a company incorporated under the laws of Nevada and having an office at 6946 N Academy Blvd., Suite B 254, Colorado Springs, CO 80918

(the “ **Company** ”)

OF THE FIRST PART

**AND:**

**Stacey R. Lewis**, having an address at 5539 West Ave L6, Quartz Hill CA 93536

(the “ **Creditor** ”)

OF THE SECOND PART

**WHEREAS:**

The Company is indebted to the Creditor via promissory note dated March 21, 2015 in the amount of US \$75,000.00 (the “ **Debt** ”),

A. As of August 20, 2015;

The Company wishes to settle \$45,000.00 of the promissory note dated March 21, 2015 in the amount of US \$75,000.00 by issuing to the Creditor, or its assigns, shares of common stock of the Company and the Creditor is prepare to accept the shares in satisfaction of \$45,000.00 of the promissory note dated March 21, 2015 in the amount of US \$75,000.00.

**NOW THEREFORE THIS AGREEMENT WITNESSES** that, in consideration of the premises and of the covenants and agreements set out in this Agreement, the parties agree as follows:

1. **ACKNOWLEDGEMENT OF DEBT**

1.1 The Company acknowledges and agrees that it is indebted to the Creditor in the amount of the Debt.

1.2 The Debt was recorded on the books of the Company on March 21, 2015.

2. **ISSUANCE OF SHARES**

2.1 The Company agrees to issue to the Creditor and the Creditor agrees to accept 45,000,000 shares of common stock of the Company (the “Shares”) at a deemed price of US \$0.001 per Share as partial payment of the promissory note dated March 21, 2015 in the amount of US \$75,000.00.

2.2 The Creditor agrees that \$45,000.00 of the Debt will be fully satisfied and extinguished when the Company delivers the Shares to the Creditor, and subject only to the issuance of the Shares, the Creditor releases and forever discharges the Company, its subsidiaries and their respective directors, officers, and employees from and against any and all claims, actions, obligations, and damages whatsoever which the Creditor may have against any of them relating to \$45,000.00 of the Debt. This release will be operative from and after the date of completion of the transaction contemplated by this Agreement and will be effective without the delivery of any further release or other documents by the Creditor to the Company.

### 3. **REPRESENTATIONS OF CREDITOR**

The Creditor represents, warrants and acknowledges to the Company that:

- (a) the Debt constitutes the outstanding indebtedness with respect to the promissory note dated March 21, 2015 in the amount of US \$75,000.00 as at February 7, 2016 including principal, interest to the date hereof and costs;
- (b) the Creditor has not conveyed, transferred or assigned any portion of the Debt to any third party, and has full right, power and authority to enter into this Agreement and to accept the Shares in full and final satisfaction of the Debt;
- (c) no third party has any right to payment of all or any portion of the Debt;
- (d) the Creditor has no claims or potential claims against the Company on account of any matter whatsoever, other than the Debt;
- (e) if the Creditor is a corporation or legal entity other than an individual, all necessary corporate or other action has been taken by the Creditor to approve this Agreement;
- (f) the Company is relying on exemptions from registration and prospectus requirements of applicable securities laws in the United States to issue the Shares to the Creditor;
- (g) the Creditor is not acquiring the Shares as a result of any material information that the Company has not generally disclosed to the public; and
- (h) the Shares will be subject to resale restrictions as required by applicable securities law and the Creditor will seek its own independent legal advice regarding such resale restrictions imposed on the Shares.

The Company's obligation to complete the transactions contemplated hereby is subject to the foregoing representations and warranties being true and correct at the date of this Agreement and at the time of closing.

Such representations and warranties will survive the closing of the transactions contemplated hereby and will continue in full force and effect for the benefit of the Company for a period of five years from the date of issuance of the Shares to the Creditor. The Creditor will indemnify the Company from and against any and all claims, damages, losses and costs arising from such representations and warranties being incorrect or breached.

### 4. **GENERAL PROVISIONS**

- 4.1 Time will be of the essence of this Agreement.
- 4.2 The Company and the Creditor will sign all other documents and do all other things reasonably necessary to carry out this Agreement.
- 4.3 The provisions contained in the Agreement constitute the entire agreement between the parties and supersede all previous understandings, communications, representations, and agreements, whether written or verbal, between the parties regarding the subject matter of this Agreement.
- 4.4 All dollar amounts referred to in this Agreement are expressed in United States currency, unless otherwise indicated.
- 4.5 This Agreement will ensure to the benefit of and be binding on each of the parties and their respective heirs, executors, administrators, successors, and assigns.
- 4.6 This Agreement may be signed in counterparts, both of which will constitute one agreement.
- 4.7 This Agreement supersedes and replaces any prior agreements between the parties concerning the subject matter hereof.

IN WITNESS WHEREOF the parties have signed this Agreement as of the date written on the first page of this Agreement.

CANNABIS SCIENCE, INC.

Per:

By: /s/ Raymond C. Dabney

Direct, CEO, President

Per:

By: /s/ Stacey R. Lewis

Stacey R. Lewis